1. Home
  2. SGRY vs HROW Comparison

SGRY vs HROW Comparison

Compare SGRY & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Surgery Partners Inc.

SGRY

Surgery Partners Inc.

HOLD

Current Price

$14.19

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

HROW

Harrow Inc.

HOLD

Current Price

$40.98

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGRY
HROW
Founded
2004
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2015
2008

Fundamental Metrics

Financial Performance
Metric
SGRY
HROW
Price
$14.19
$40.98
Analyst Decision
Buy
Strong Buy
Analyst Count
8
8
Target Price
$22.25
$69.86
AVG Volume (30 Days)
2.2M
539.0K
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
54.14
71.43
EPS
N/A
N/A
Revenue
$1,145,438,000.00
N/A
Revenue This Year
$5.09
$31.62
Revenue Next Year
$5.67
$50.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.41
$28.54
52 Week High
$23.66
$54.98

Technical Indicators

Market Signals
Indicator
SGRY
HROW
Relative Strength Index (RSI) 41.41 53.97
Support Level $13.45 $40.65
Resistance Level $15.24 $42.11
Average True Range (ATR) 0.84 1.96
MACD -0.17 0.26
Stochastic Oscillator 20.67 68.13

Price Performance

Historical Comparison
SGRY
HROW

About SGRY Surgery Partners Inc.

Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: